Advanced Solid Malignancies Completed Phase 1 Trials for Dusigitumab (DB12363)

Also known as: Advanced Solid Malignancy

IndicationStatusPhase
DBCOND0034803 (Advanced Solid Malignancies)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01340040Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese SubjectsTreatment